S
Salih Zeki Guclu
Publications - 16
Citations - 520
Salih Zeki Guclu is an academic researcher. The author has contributed to research in topics: Erlotinib & Afatinib. The author has an hindex of 6, co-authored 15 publications receiving 442 citations.
Papers
More filters
Journal ArticleDOI
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Jean-Charles Soria,Enriqueta Felip,Manuel Cobo,Shun Lu,Konstantinos N. Syrigos,Ki Hyeong Lee,Erdem Göker,Vassilis Georgoulias,Wei Li,Dolores Isla,Salih Zeki Guclu,Alessandro Morabito,Young Joo Min,Andrea Ardizzoni,Shirish M. Gadgeel,Bushi Wang,Vikram K. Chand,Glenwood D. Goss +17 more
TL;DR: In this paper, an open-label, phase 3 randomised controlled trial at 183 cancer centres in 23 countries worldwide was conducted to compare erlotinib (a reversible EGFR tyrosine kinase inhibitor) with afatinib (40 mg per day) until disease progression.
Journal ArticleDOI
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Glenwood D. Goss,Enriqueta Felip,Manuel Cobo,Shun Lu,Konstantinos N. Syrigos,Ki Hyeong Lee,Erdem Göker,Vassilis Georgoulias,Wei Li,Salih Zeki Guclu,Dolores Isla,Young Joo Min,Alessandro Morabito,Andrea Ardizzoni,Shirish M. Gadgeel,Andrea Fülöp,Claudia Bühnemann,Neil W. Gibson,Nicole C. Krämer,Flavio Solca,Agnieszka Cseh,E. Ehrnrooth,Jean-Charles Soria +22 more
TL;DR: Next-generation sequencing may help identify patients with lung squamous cell carcinoma who would derive additional benefit from treatment with afatinib, and the role of ERBB mutations, particularly HER2 mutations, as predictive biomarkers for afatinIB treatment in this setting warrants further evaluation.
Journal ArticleDOI
Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey.
Elif Sen,Salih Zeki Guclu,Isil Kibar,Ulku Ocal,Veysel Yilmaz,Onur Celik,Filiz Cimen,Fusun Topcu,Meltem Orhun,Hikmet Tereci,Aylin Konya,Idilhan Ar,Sevgi Saryal +12 more
TL;DR: Pulmonologists in Turkey have low rates of adherence to GOLD guidelines in COPD treatment, andappropriateness of therapies was due to overtreatment in early stages and excessive use of inhaled corticosteroid in all disease stages.
Journal ArticleDOI
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
Suresh S. Ramalingam,Silvia Novello,Salih Zeki Guclu,Dmitry Bentsion,Zanete Zvirbule,Mária Szilasi,R. Bernabé,Konstantinos N. Syrigos,Lauren Averett Byers,Philip Clingan,Jair Bar,Everett E. Vokes,Ramaswamy Govindan,Martin Dunbar,Peter Ansell,Lei He,Xin Huang,Vasudha Sehgal,Jaimee Glasgow,Bruce A. Bach,Julien Mazieres +20 more
TL;DR: In this article, the efficacy and safety of poly (ADP-ribose) polymerase in non-small-cell lung cancer (sqNSCLC) was investigated using a phase III study.
Journal ArticleDOI
Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).
Jean-Charles Soria,Enriqueta Felip,Manuel Cobo,Shun Lu,Konstantinos N. Syrigos,Ki Hyeong Lee,Erdem Göker,Vassilis Georgoulias,Wei Li,Dolores Isla,Salih Zeki Guclu,Alessandro Morabito,Young Joo Min,Andrea Ardizzoni,Shirish M. Gadgeel,Bushi Wang,Vikram K. Chand,Glenwood D. Goss,LUX-Lung Investigators +18 more
TL;DR: Primary analysis of LL8 showed significantly better progression-free survival (PFS) with A, while OS was significantly better with A vs E, with a 19% better chance of survival than E.